506 related articles for article (PubMed ID: 31243259)
21. Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Silva-Fernández L; De Cock D; Lunt M; Low AS; Watson KD; ; Symmons DPM; Hyrich KL
Rheumatology (Oxford); 2018 Sep; 57(9):1533-1540. PubMed ID: 28968862
[TBL] [Abstract][Full Text] [Related]
22. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.
Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
Arthritis Rheumatol; 2017 Jun; 69(6):1154-1164. PubMed ID: 28245350
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register.
Chatzidionysiou K; Askling J; Eriksson J; Kristensen LE; van Vollenhoven R;
Ann Rheum Dis; 2015 May; 74(5):890-6. PubMed ID: 24431398
[TBL] [Abstract][Full Text] [Related]
24. Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Favalli EG; Sinigaglia L; Becciolini A; Grosso V; Gorla R; Bazzani C; Atzeni F; Sarzi Puttini PC; Fusaro E; Pellerito R; Caporali R
Int J Rheum Dis; 2018 Feb; 21(2):422-430. PubMed ID: 29082659
[TBL] [Abstract][Full Text] [Related]
25. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
Wadström H; Frisell T; Askling J;
JAMA Intern Med; 2017 Nov; 177(11):1605-1612. PubMed ID: 28975211
[TBL] [Abstract][Full Text] [Related]
26. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs.
Strangfeld A; Richter A; Siegmund B; Herzer P; Rockwitz K; Demary W; Aringer M; Meißner Y; Zink A; Listing J
Ann Rheum Dis; 2017 Mar; 76(3):504-510. PubMed ID: 27405509
[TBL] [Abstract][Full Text] [Related]
27. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of golimumab for rheumatoid arthritis in patients with an inadequate response to tocilizumab.
Matsuno H; Katayama K
Mod Rheumatol; 2017 Mar; 27(2):246-251. PubMed ID: 27550060
[TBL] [Abstract][Full Text] [Related]
29. Predictors and causes of first-line biologic agent discontinuation in rheumatoid arthritis: data from Reuma.pt.
Gomes JL; Sepriano A; Eusébio M; Serra S; Fonseca JE; Saavedra MJ; Cunha-Miranda L; Silva C; Bernardes M; Rosa-Gonçalves D; Costa J; Castelão W; Branco JC; Santos MJ
Acta Reumatol Port; 2019; 44(1):57-64. PubMed ID: 31249276
[TBL] [Abstract][Full Text] [Related]
30. Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis.
Ogawa Y; Takahashi N; Kaneko A; Hirano Y; Kanayama Y; Yabe Y; Oguchi T; Fujibayashi T; Takagi H; Hanabayashi M; Funahashi K; Hayashi M; Tsuboi S; Asai S; Asai N; Matsumoto T; Sobue Y; Ishiguro N; Kojima T
Clin Rheumatol; 2019 Oct; 38(10):2757-2763. PubMed ID: 31179526
[TBL] [Abstract][Full Text] [Related]
31. Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study.
Choy EH; Bernasconi C; Aassi M; Molina JF; Epis OM
Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1484-1494. PubMed ID: 28622454
[TBL] [Abstract][Full Text] [Related]
32. Retention of tocilizumab with and without methotrexate during maintenance therapy for rheumatoid arthritis: the ACTRA-RI cohort study.
Mori S; Yoshitama T; Abe Y; Hidaka T; Hirakata N; Aoyagi K; Ueki Y
Rheumatology (Oxford); 2019 Jul; 58(7):1274-1284. PubMed ID: 30793749
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of a Second Biologic After Failure of a Non-tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis.
Chatzidionysiou K; Hetland ML; Frisell T; Di Giuseppe D; Hellgren K; Glintborg B; Nordström D; Peltomaa R; Aaltonen K; Trokovic N; Kristianslund EK; Kvien TK; Provan SA; Gudbjornsson B; Grondal G; Dreyer L; Kristensen LE; Jørgensen TS; Jacobsson LTH; Askling J
J Rheumatol; 2021 Oct; 48(10):1512-1518. PubMed ID: 33649069
[TBL] [Abstract][Full Text] [Related]
34. Drug-survival profiling of second-line biologic therapy in rheumatoid arthritis: Choice of another tumour necrosis factor inhibitor or a biologic of different mode of action?
Shipa MRA; Di Cicco M; Balogh E; Nitu NA; Mainuddin MD; Bhadauria N; Mukerjee D; Roussou E
Mod Rheumatol; 2023 Jul; 33(4):700-707. PubMed ID: 35920402
[TBL] [Abstract][Full Text] [Related]
35. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries.
Courvoisier DS; Chatzidionysiou K; Mongin D; Lauper K; Mariette X; Morel J; Gottenberg JE; Bergstra SA; Suarez MP; Codreanu C; Kvien TK; Santos MJ; Pavelka K; Hetland ML; Askling J; Turesson C; Kubo S; Tanaka Y; Iannone F; Choquette D; Nordström DC; Rotar Z; Lukina G; Gabay C; Van Vollenhoven R; Finckh A
Rheumatology (Oxford); 2021 Feb; 60(2):820-828. PubMed ID: 32810263
[TBL] [Abstract][Full Text] [Related]
36. Non-TNF inhibitor switchers versus TNF inhibitor cyclers from multicentre rheumatoid arthritis ultrasonography prospective cohort in Japan.
Endo Y; Kawashiri SY; Morimoto S; Nishino A; Okamoto M; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Igawa T; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Tsuru T; Nagano S; Arinobu Y; Hidaka T; Tada Y; Kawakami A
Immunol Med; 2020 Sep; 43(3):115-120. PubMed ID: 32393150
[TBL] [Abstract][Full Text] [Related]
37. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
Xie F; Yun H; Bernatsky S; Curtis JR
Arthritis Rheumatol; 2016 Nov; 68(11):2612-2617. PubMed ID: 27213279
[TBL] [Abstract][Full Text] [Related]
38. Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice.
Backhaus M; Kaufmann J; Richter C; Wassenberg S; Roske AE; Hellmann P; Gaubitz M
Clin Rheumatol; 2015 Apr; 34(4):673-81. PubMed ID: 25630309
[TBL] [Abstract][Full Text] [Related]
39. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.
Ebina K; Hashimoto M; Yamamoto W; Ohnishi A; Kabata D; Hirano T; Hara R; Katayama M; Yoshida S; Nagai K; Son Y; Amuro H; Akashi K; Fujimura T; Hirao M; Yamamoto K; Shintani A; Kumanogoh A; Yoshikawa H
PLoS One; 2018; 13(3):e0194130. PubMed ID: 29543846
[TBL] [Abstract][Full Text] [Related]
40. Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry.
Monti S; Klersy C; Gorla R; Sarzi-Puttini P; Atzeni F; Pellerito R; Fusaro E; Paolazzi G; Rocchetta PA; Favalli EG; Marchesoni A; Caporali R
Clin Rheumatol; 2017 Apr; 36(4):753-761. PubMed ID: 28058538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
